![]() |
Re: Coronavirus
Quote:
Yes, no surprise really, forever the pessimist. |
Re: Coronavirus
Quote:
Link Quote:
---------- Post added at 20:13 ---------- Previous post was at 20:00 ---------- Quote:
Eg UK in July Quote:
Quote:
|
Re: Coronavirus
Quote:
But I won’t make any of those observations because there’s inevitably an element of risk and gambling in a situation like this. What this shows us is that you win some and you lose some. What it doesn’t tell us is anything remotely useful about the supposed benefit of a common European medicines procurement policy. |
Re: Coronavirus
Quote:
|
Re: Coronavirus
Quote:
The interesting thing about Germany here isn’t just that they failed to secure early backing for the RNA vaccine part-developed by a German company (BioNTech), but now the EU has bought in to the Pfizer/BioNTech vaccine Germany is getting the lion’s share of the first delivery. It strikes me as a strange definition of “acting together” given that Germany’s Covid transmission rate is and always has been far lower than many other places. A cynic might say that the EU’s much trumpeted joint approach is a fig leaf covering the unedifying (but entirely understandable) spectacle of member states looking after their own interests in an area where there isn’t actually any EU competency, but because it’s a crisis they feel like they should be seen to be Doing Something. Germany is more or less getting what it has paid for, with lip service paid to pooling and sharing resources and precious little evidence of the vaccine going exactly where it’s needed. |
Re: Coronavirus
https://ec.europa.eu/info/live-work-...blic-health_en
The EU look in a good position to me. I hope they are in a good position because they're ordering significant numbers of many of the same products and it's in our mutual interests to get the virus under control. The more products the better as there's a likelihood we could all be scraping around in 12-24 months for additional doses. |
Re: Coronavirus
Quote:
Quote:
Quote:
|
Re: Coronavirus
Quote:
The EU plausibly has a price per unit advantage if it is able to put down significantly larger orders, but given that no vaccines have yet been produced, demand massively outstrips supply and the politics of where vaccines are being developed and manufactured also plays a part, that’s by no means guaranteed. What interests me most here is the EU’s internal politics. Who pays for the vaccine and who gets it first? From what I’ve read so far, it isn’t likely to be down to plain and simple pooling and sharing. |
Re: Coronavirus
Quote:
I'd also expect Germany to be better placed to immediately distribute massive numbers of a vaccine that requires such cold storage throughout it's distribution chains. Scattering it round the continent is going to be a logistical challenge that I'd imagine is undesirable and perhaps unnecessary is other vaccines are in the pipeline that don't have the same issues. I agree with you on the UK vs EU part of this though - pointless as you say everyone is gambling to a greater or lesser degree on big names and smaller companies. ---------- Post added at 20:58 ---------- Previous post was at 20:57 ---------- Quote:
On the per unit cost point I'm inclined to agree that even where it arises it's going to be so small compared to the economic impact of Covid. Even $20 (going high deliberately) for 45 million people (rough population immunity threshold). It's nothing. |
Re: Coronavirus
Quote:
|
Re: Coronavirus
Quote:
|
Re: Coronavirus
Buying a portfolio of vaccines obviously makes sense and the UK seems to have done a good job here.
However, from the information below, it does appear that the EU was able to buy from Moderna but the UK struggled. Quote:
|
Re: Coronavirus
Quote:
Quote:
|
Re: Coronavirus
The Grauniad reports that what the EU has had since summer is a “potential purchase agreement” for Moderna’s vaccine.
https://www.theguardian.com/world/20...-covid-vaccine That’s somewhat less concrete than the firm pre-order HMG has placed with Pfizer. The government has cited higher cost, potential supply chain issues in Europe, and Moderna’s refusal to sign any actual supply contracts outside the USA as reasons for concentrating on Pfizer. It also quite reasonably points out that it therefore has an RNA vaccine in its portfolio. Pfizer’s cooperation with BioNTech on this project also means there will initially be two European manufacturing bases for it so there’s no chance of the US government slapping an export ban on the product to give their own population priority. |
Re: Coronavirus
The nice thing about the EU is that there communications are pretty upfront. Here is their vaccine strategy page - https://ec.europa.eu/info/live-work-...blic-health_en
Here's a short summary; Contracts in place AstraZeneca/Oxford vaccine - contact for 300million doses plus option for an additional 100million Sanofi/GSK - 300million doses Janssen - 200million doses plus option for an additional 200million BioNTech/Pfizer - 200million doses plus option of an additional 100million Talks in place; Moderna - 80million doses Curevac - 225million doses The Sanofi/GSK one is the safe bet. The BioNTech, Moderna and Curevac ones are all mRNA vaccines which are a new technology but seem to give a storming immune response. The Janssen and AZ/Oxford ones are the 'risky' bets. Looking through the candidates out there, there are some strange vaccines in trials right now! |
All times are GMT +1. The time now is 07:35. |
Powered by vBulletin® Version 3.8.11
Copyright ©2000 - 2025, vBulletin Solutions Inc.
All Posts and Content are © Cable Forum